# Shaquille O'Neal Credits Zepbound for Improving Sleep Apnea and Weight
Shaquille O'Neal recently shared how the weight loss medication Zepbound (tirzepatide) has helped address both his sleep apnea and excess weight. The NBA legend's experience highlights an emerging benefit of GLP-1 receptor agonists and dual GIP/GLP-1 agonists beyond simple weight reduction.
Sleep apnea occurs when airways collapse during sleep, interrupting breathing and fragmenting rest. Excess weight worsens the condition by narrowing airways. When patients lose weight through medications like Zepbound, sleep apnea often improves dramatically. O'Neal's case reflects what sleep medicine specialists regularly observe in clinical practice.
Zepbound (tirzepatide) works as a GIP/GLP-1 receptor agonist, meaning it mimics two natural hormones that regulate appetite and blood sugar. The medication was approved by the FDA in 2023 for chronic weight management. Clinical trials showed people using Zepbound lost 20 to 21 percent of their body weight over 68 weeks, compared to 2.4 percent with placebo.
The sleep apnea connection matters for parents and families managing metabolic conditions. Children and teens with obesity face rising rates of sleep apnea, which disrupts growth, school performance, and mood. While Zepbound is approved only for adults aged 18 and older, understanding how weight loss impacts sleep quality informs broader family health conversations.
O'Neal's openness about using Zepbound normalizes medication as a legitimate weight management tool, not a personal failure. However, the medication carries real considerations. Common side effects include nausea, vomiting, and constipation. Some users experience pancreatitis